These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 16540013)

  • 41. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
    Pauwels EK; Erba P
    Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
    Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
    J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
    Hagenbeek A
    Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radioimmunotherapy for B-cell non-hodgkin lymphomas.
    Tomblyn M
    Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life.
    Andrade-Campos MM; Montes-Limón AE; Soro-Alcubierre G; Grasa JM; Lopez-Gómez L; Baringo T; Giraldo P
    Ann Hematol; 2014 Dec; 93(12):1985-92. PubMed ID: 24985089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
    Witzig TE; Molina A; Gordon LI; Emmanouilides C; Schilder RJ; Flinn IW; Darif M; Macklis R; Vo K; Wiseman GA
    Cancer; 2007 May; 109(9):1804-10. PubMed ID: 17380530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
    Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
    Micallef IN
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S27-32. PubMed ID: 15498147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond.
    Evens AM; Gordon LI
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S11-5. PubMed ID: 15498144
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab.
    Sjögreen-Gleisner K; Dewaraja YK; Chiesa C; Tennvall J; Lindén O; Strand SE; Ljungberg M
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):126-54. PubMed ID: 21386787
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
    Ghobrial I; Witzig T
    Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.
    Leonard JP
    Hematology Am Soc Hematol Educ Program; 2005; ():335-9. PubMed ID: 16304400
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
    Kawashima H
    ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
    Macklis RM
    Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Zimmer AM
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma.
    Jacobs SA; Harrison AM; Swerdlow SH; Foon KA; Avril N; Vidnovic N; Joyce J; DeMonaco N; McCarty KS
    Mol Imaging Biol; 2009; 11(1):39-45. PubMed ID: 18773247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    White CA
    Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab].
    Aurer I; Huić D; Zuvić M; Sever-Prebilić M; Ajduković R; Radman I; Skare-Librenjak L; Ostojić-Kolonić S; Labar B
    Lijec Vjesn; 2006; 128(7-8):224-7. PubMed ID: 17087138
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
    Chinn PC; Leonard JE; Rosenberg J; Hanna N; Anderson DR
    Int J Oncol; 1999 Nov; 15(5):1017-25. PubMed ID: 10536187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.